14TH ALIMS SYMPOSIUM
OCT 5-6, 2018, Serbia
Optimapharm is attending the 14th traditional international symposium ALIMS, in Kragujevac.
Meet with our Serbian team to discuss how to transform vision into practice in the regulation of medicines and medical devices.
CLINICAL TRIALS QUALITY & COMPLIANCE CONFERENCE
VIENNA SEP 13-14, 2018
Optimapharm is attending the 3rd annual Clinical Trials Quality & Compliance Conference in Vienna,
Meet us to exchange ideas on achieving inspection readiness and compliance in clinical quality and to discuss our services and support in running clinical trials.
Optimapharm is attending 4th European Conference on Clinical Research in Vienna, Austria.
Meet us to discuss our services and support in running clinical trials in the European emerging region.Contact Us
Outsourcing in Clinical Trials
West Coast, 21-22 February 2018
Optimapharm is attending Outsourcing in Clinical Trials West Coast, 21-22 February 2018.
Contact us to arrange a meeting to discuss latest achievements in clinical trials in Europe.
Maxime Stevens has an excess of 25 years’ experience in executive leadership and has impacted long-term
growth, operational excellence, and the expansion of new geographic and channel opportunities for
significant companies in industry. Her extensive international experience has been gained particularly in
EMEA, Israel, South Africa, Europe and the US.
Maxime ran Operations Southern Africa for W.H.O (World Health Organization) for seven years, developing medical programs, charities and NGO’s across several countries. She then returned to the UK, moving across into clinical research and accelerating from International Head of Business Development through to CEO of a global CRO within five years. In addition to building, restructuring and growing sales and operational teams, she has been instrumental in managing M&A’s, and led the disaster management of a failing global company with 24 offices and 800 staff, which then became SIX listed 18 months later under her management.
Maxime has dual nationality with South Africa and the UK. She received the W.H.O award for Outstanding Contribution to Ethics in Business and Humanity and was an Honored Member of International WHO’s WHO of Professionals in both 2013 and 2014.
With this appointment, Optimapharm is further strengthening its Business Development team with a strong focus on expertise and capability to offer good-quality and time-focused tailor-made solutions to the most diverse demands of clinical research for both pharma and biotech companies.
Optimapharm is pleased to announce the expansion of its office network and business development team and the appointment of Mr. Roy Ovel, an expert in business development, as Chief Commercial Officer.
Roy is a customer focused, commercially aware entrepreneurial leader with over 35 years’ experience in the CRO industry, specialized in providing full-service solutions to pharma and biotech companies during which, he has held numerous senior leadership positions at local CROs as well as larger multinational CROs (ICON & Worldwide Clinical Trials). His experience spans preclinical through to late phase research and covers the whole drug development continuum.
Roy has a BSc (Hons) in Life Sciences from Napier University, Edinburgh and has a reputation for managing high performing global business development teams to ensure business growth whilst focusing on the needs of the customer.
“Roy joining the company, will significantly strengthen our business development activities as he has experience of working globally with virtual as well as large pharma across the drug development continuum. His reputation as a leader with strong commercial acumen focussed on working with customers to really meet their needs is key in an environment where demands on pharmaceutical and biotech customers continues to grow. Our continued focus on quality and expedited patient recruitment and retention has led to a 95% repeat business rate. This combined with our strong track record for operational excellence has allowed us to appoint Roy to help continue our growth in both Europe and the United States” Optimapharm CEO, Gordana Gregurić Čičak, said.
Roy has worked for both small local CROs as well as the larger CROs and his experience in meeting client’s challenges and ensuring the growth of companies is aligned with client needs has been the key to Roy’s success. He is highly customer focused with an ability to take a holistic approach to business.
“Here at Optimapharm, the combination of expertise across our teams is why we feel confident in offering good-quality and time-focused tailor-made solutions to the most diverse demands of clinical research for both pharma and biotech companies. That’s our competitive advantage and it will definitely be recognized by our customers whilst the timely recruitment of patient continues to be a significant challenge. I am really excited at the prospect of offering real expedited patient recruitment strategies to our customers, as my experience is that, this continues to be a significant hurdle to our clients meeting their milestones. ” Optimapharm Chief Commercial Officer, Roy Ovel, added.
For more information, contact Roy Ovel directly on +44 (0)7789 40 20 80 or e mail firstname.lastname@example.org
Chris is a seasoned financial professional with over 20 years’ experience in providing structured finance and equity capital to companies in both Western and Central & Eastern Europe. Chris is British and lives in Prague. He holds a Bachelor of Science degree from Loughborough University and a Diploma in Marketing.
Since 2005 Chris has been a partner at Mezzanine Management, the first dedicated mezzanine fund manager for Central and Eastern Europe. It manages four funds with total funds raised of over EUR 650 million. The latest fund, AMC Capital Capital IV ScSP was established in mid-2017. The four funds have made 49 investments in 12 countries of the central and eastern European region to date.
BBetween 2000 and 2005 Chris was head of Acquisition Finance, Central and Eastern Europe at Erste Bank where he was a pioneer in the region’s fledgling acquisition finance market.
Before joining Erste Bank in 1997, he was an Investment Manager at HSBC Ventures, a private equity operation focusing on small buy-outs in the UK.
We are extremely pleased to have Chris joining our Board.
For further information please contact:
Human Resources Manager
Phone: +385 1 5553 600
Optimapharm is a leading regional clinical research organization (CRO) in the SEE markets. Over the next three years,
Optimapharm plans to double its revenues via organic growth and add on acquisitions to become the largest
independent CRO in the whole of CEE
Following the global trend of consolidating market positions of clinical research organizations (CROs), Optimapharm, the leading CRO in SEE, acquired the Czech CRO company MKS Research.
By acquiring MKS Research, Optimapharm will enter the Czech market, and further strengthen its portfolio of clients in the pharmaceutical and biotech industries and its market position in Central Europe. The move is in line with Optimapharm’s medium-term strategic objective of becoming the largest independent CRO in CEE, with business operations across Europe and the U.S.
“The clinical research market is experiencing a continued rise, and we have the knowhow, references and strong financial position enabling us to lead the consolidation in the region. Moreover, our ambition is to double our revenues over the next three years, and continue acquiring good-quality companies such as MKS Research,” Optimapharm CEO Gordana Gregurić Čičak said.
By consolidating MKS Research, Optimapharm will have a total of 120 full-time employees and annual revenues over EUR 12 million. Optimapharm is headquartered in Zagreb, Croatia, and has offices in more than ten European countries. It covers markets with over 200 million people and has the expertise to conduct phase I – IV clinical research across Europe and through partners in the U.S.
“We are becoming a part of a much larger company with structured operational support. This means that we will be even better able to focus on projects and growth in the Czech and Slovak markets, while our employees will get new opportunities to develop their careers within an international group and work on more complex projects,” MKS Research executive director Veronika Sebkova stated.
The value of the global clinical research market has been growing in the last several years at annual rates of more than 10 percent. In 2016, it reached USD 31.4 billion. It is expected to reach USD 49.26 billion in the 2017 – 2021 period (New Market Research Report, December 2017). The biggest market is the U.S., accounting for 40 percent of the global market, with Europe being the second biggest one.
Optimapharm is the biggest independent clinical research organization in Southeast Europe. It was founded in 2005 in Zagreb, and has since built up a professional multidisciplinary team with expertise in clinical research in the pharmaceutical, biotech and medical device industries. More than 60 percent of employees have more than six years of experience in relevant clinical research, while more than a third of all employees are doctors in various fields of medicine and life sciences.
Optimapharm has taken part in many international clinical programs that resulted in commercialization of new drugs in the segments of oncology, cardiovascular diseases, metabolic diseases, pulmonology, psychiatry and neurology. Optimapharm has a strong track record in conducting pediatric clinical trials in various indications. The company has the most expertise in clinical research in the field of oncology, cardiovascular and metabolic diseases.
For more information, visit www.optimapharm.eu.
Recognizing needs for further expansion to meet the specific requirements of our customers,
OPTIMAPHARM, the largest Central and South-Eastern European Clinical Research Organisation,
established legal entity and office - in Tbilisi, Georgia and Sofia, Bulgaria.
A significant effort has been made to improve Georgia’s healthcare policy and system in recent years, offering a great potential for running clinical trials in this region and at the same time creating a huge opportunity for the patients to have access to the latest treatments. Therefore, OPTIMAPHARM decided to be a part of these positive developments and to facilitate trial acquisition and execution upon the request of clients. Bulgaria’s presence reinforces OPTIMAPHARM’s intention to increase the capacity of Clinical Operations and to strengthen the presence in Central and South-Eastern Europe.
Having operations across 10 leading countries in the region and offering a full range of clinical trial services from fast patient recruitment, clinical trial design, management and monitoring, to regulatory affairs and data management and analysis, OPTIMAPHARM is recognized as an excellent partner for conducting trials within Emerging regions in Europe.
'We want to support our clients with their plans to conduct cost-efficient and fast enrolling trials and we pay close attention to a more personalized approach to trial execution. By opening new sites with additional resources, we believe this will significantly help in our efforts to provide fast and high quality services for our clients', says Gordana Greguric Cicak, CEO at OPTIMAPHARM.
Business Development Officer
OPTIMAPHARM continues to expand the Clinical Operations team by appointing Ivaylo Yordanov as Country Manager in Bulgaria.
Ivaylo is a skilled Clinical Research professional with over 10 years of experience in one of the top global pharmaceutical companies. Working as a Clinical Research Associate, specializing in Diabetes, Hemophilia, Obesity and Non-alcoholic steatohepatitis, Ivaylo demonstrated exceptional leadership skills and motivation thus advancing initially to Local and later becoming the Regional Trial Manager and finally to the position of Clinical Research Manager at Novo Nordisk, Bulgaria. Ivaylo will supervise and coordinate the complex and challenging activities related to the clinical trial execution where the combination of both clinical research expertise and effective management skills are needed.
A strong and experienced team is key to reaching our ambitions and fulfilling high expectations from our clients. Ivaylo brings a strong know-how in managing clinical research projects making him a great addition to our team as we accelerate the growth of OPTIMAPHARM.
For further information please contact:
Human Resources Manager
Phone:+385 1 5553 600
As a part of the growing strategy, OPTIMAPHARM announced the expansion of its senior
management team through appointment of Goran Vesov, MD as Director of the Quality
assurance and training department.
Goran brings over 17 years of experience in research and pharmaceutical industry. He has a medical background and is a specialist in Paediatrics. His career in drug development started in Novo Nordisk, where he moved from CRA to various leadership positions - such as Clinical Quality and Training Manager, Clinical Research Manager and Head of Clinical Europe East. In 2013 he started working in the Novo Nordisk European HQ in Zurich as a Senior Quality and Education Manager, the position he held until he joined Optimapharm. During his career, Goran has provided quality control/support and training around the globe, acquiring thorough insight in these processes. To develop his leadership skills, Goran has graduated at the prestigious Scandinavian International Management Institute in Copenhagen.
With his experience and knowledge, he is the right person to accelerate the development of Optimapharm by strongly contributing to the advancement of our quality and training systems.
For further information please contact:
Human Resources Manager
Optimapharm, the largest Central and South-Eastern European Clinical Research provider,
continues to offer broad and high quality services to accelerate ambitious clinical
development programs for their Clients. As a result of growing demand for emerging
markets, an office has been opened in Ljubljana, Slovenia in June 2017 and a new, larger
office has been acquired in Skopje, Macedonia in May 2017.
With the increasing capacity of Clinical Operations and strengthening of presence in Central and South-Eastern Europe, Optimapharm has gained considerable strategic value to support the Clients’ growing demand. Optimapharm currently employs over 100 experienced clinical trial professionals covering 12 countries throughout Europe . Optimapharm offers wide range of services across all functional areas including Clinical Operations, Regulatory & Ethics, Clinical Project Management, Quality Assurance, Data Management, Bio-Statistics, Medical Writing and Pharmacovigilance for clinical trials Phases I-IV and non-interventional studies.
Commenting on the investment, Gordana Greguric Cicak, CEO at Optimapharm said: ‘This is a valuable strategic investment for Optimapharm as there is a high demand for conducting clinical research in our region because pharma and biotech companies continue to recognise value of emerging regions.’
Josipa Bello, PhD
Business Development Officer
Mobile: +32 473 51 83 70
Apart from being key regional partner in cutting edge medical research we do not forget to engage as a responsible corporate citizen of the global community. This year again we will be supporting Motovun Film Festival. As primarily dedicated to the films from small cinematographers and independent productions, films that have a hard time fighting their way to theaters and wide audiences, this festival celebrates the authors sticking to their artistic stubbornness, unconventionality and originality. It will take place in small and beautiful medieval town Motovun in Istria, end of July